Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Crona J
Authors: Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C,
Keywords: tumor growth rate, TGR, RECIST, Neuroendocrine Tumor,
Introduction: TGR (% change in tumour volume per month (%/m)) is postulated to be an early radiological biomarker to overcome limitations of RECIST in NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Lamarca A
Authors: Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C,
Keywords: tumor growth rate, response, progression-free survival, follow-up, neuroendocrine tumor, prognosis, TGR, RECIST, radiology,
Introduction: EVE-induced HG can be explained by a decrease in insulin release or increase in peripheral insulin resistance. It has been documented in 12-13% of NET pts included in phase III clinical trials based on investigators reports.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Custodio A
Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,
Keywords: NET, everolimus, hyperglycemia ,
Introduction: MET has shown antitumorigenic effects on DM cancer pts, which are mediated by decrease of insulin/IGF-1 levels and activation of the AMPK pathway leading to mTOR inactivation.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Custodio A
Authors: Custodio A, Jiménez-Fonseca P, Alonso-Orduña V, López López C, Alonso T,
Keywords: NET, diabetes, metformin, everolimus,